NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
ZA763131B
(en)
*
|
1975-05-27 |
1978-01-25 |
Syntex Inc |
Use of flunisolide to treat respiratory diseases
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
HU221584B
(hu)
*
|
1993-01-08 |
2002-11-28 |
Aktiebolaget Astra |
Új vastagbél- (colon) vagy csípőbél- (ileum) specifikus, cukortartalmú szteroidszármazékok, ezeket tartalmazó gyógyszerkészítmények és előállításuk
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
CA2537185A1
(en)
*
|
2003-08-29 |
2005-03-10 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-iv
|
EP1694655A2
(en)
*
|
2003-11-26 |
2006-08-30 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
EP1737861A4
(en)
|
2004-04-09 |
2010-04-28 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
EP1888050B1
(en)
|
2005-05-17 |
2012-03-21 |
Merck Sharp & Dohme Ltd. |
cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
|
WO2007031838A1
(en)
|
2005-09-16 |
2007-03-22 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
RU2008119322A
(ru)
*
|
2005-10-19 |
2009-11-27 |
Рэнбакси Лабораториз Лимитед (In) |
Композиции ингибиторов фосфодиэстеразы iv типа
|
EP1948164A1
(en)
|
2005-10-19 |
2008-07-30 |
Ranbaxy Laboratories, Ltd. |
Pharmaceutical compositions of muscarinic receptor antagonists
|
US20100029728A1
(en)
*
|
2006-09-22 |
2010-02-04 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
CN101616901A
(zh)
*
|
2006-09-22 |
2009-12-30 |
兰贝克赛实验室有限公司 |
Iv型磷酸二酯酶的抑制剂
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
AU2007340129B2
(en)
|
2006-12-26 |
2012-02-02 |
Pharmacyclics Llc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
BRPI0806245B1
(pt)
|
2007-01-10 |
2022-01-25 |
Msd Italia S.R.L. |
Compostos de fórmula i e seus usos
|
EP1958947A1
(en)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type 4
|
US20110130403A1
(en)
*
|
2007-03-14 |
2011-06-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
SI2124944T1
(sl)
|
2007-03-14 |
2012-05-31 |
Ranbaxy Lab Ltd |
Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
AU2010294598B2
(en)
*
|
2009-09-11 |
2016-09-01 |
Chiesi Farmaceutici S.P.A. |
Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
JP2013518909A
(ja)
|
2010-02-08 |
2013-05-23 |
キナゲン,インク. |
アロステリックキナーゼ阻害が関係する治療方法および組成物
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
CN103068980B
(zh)
|
2010-08-02 |
2017-04-05 |
瑟纳治疗公司 |
使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制
|
CA2807307C
(en)
|
2010-08-17 |
2021-02-09 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
SG2014014419A
(en)
|
2011-09-13 |
2014-07-30 |
Pharmacyclics Inc |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
EP3453762B1
(en)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
RU2698197C2
(ru)
|
2012-08-24 |
2019-08-23 |
Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем |
Гетероциклические модуляторы активности hif для лечения заболеваний
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
BR112015006990A2
(pt)
|
2012-09-28 |
2017-07-04 |
Merck Sharp & Dohme |
composto, composição farmacêutica, e, uso de pelo menos um composto
|
ME02925B
(me)
|
2012-11-28 |
2018-04-20 |
Merck Sharp & Dohme |
Kompozicije i postupci za liječenje kancera
|
ES2707305T3
(es)
|
2012-12-20 |
2019-04-03 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de HDM2
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2017222951A1
(en)
|
2016-06-23 |
2017-12-28 |
Merck Sharp & Dohme Corp. |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
AU2017359043B2
(en)
|
2016-11-08 |
2022-06-16 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
MX2019013690A
(es)
|
2017-05-18 |
2020-01-27 |
Regeneron Pharma |
Conjugados de farmaco-proteina con ciclodextrina.
|
CA3098453A1
(en)
|
2018-05-09 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-msr1 antibodies and methods of use thereof
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
CA3160153A1
(en)
|
2019-12-17 |
2021-06-24 |
Michelle Machacek |
Prmt5 inhibitors
|
WO2024049931A1
(en)
|
2022-09-02 |
2024-03-07 |
Merck Sharp & Dohme Llc |
Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
|
WO2024091437A1
(en)
|
2022-10-25 |
2024-05-02 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|